Progesterone after previous preterm birth for prevention of neonatal respiratory distress syndrome (PROGRESS): a randomised controlled trial by Dodd, Jodie M et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Pregnancy and Childbirth
Open Access Study protocol
Progesterone after previous preterm birth for prevention of 
neonatal respiratory distress syndrome (PROGRESS): a 
randomised controlled trial
Jodie M Dodd*1, Caroline A Crowther1, Andrew J McPhee2, Vicki Flenady3 
and Jeffrey S Robinson1
Address: 1Discipline of Obstetrics and Gynaecology, The University of Adelaide, Adelaide, SA, Australia, 2Department of Neonatology, The 
Women's and Children's Hospital, Adelaide, SA, Australia and 3Centre for Clinical Studies, Mater Health Services, Brisbane, SA, Australia
Email: Jodie M Dodd* - jodie.dodd@adelaide.edu.au; Caroline A Crowther - caroline.crowther@adelaide.edu.au; 
Andrew J McPhee - mcpheea@wch.sa.gov.au; Vicki Flenady - vicki.flenady@mater.org.au; Jeffrey S Robinson - jeffrey.robinson@adelaide.edu.au
* Corresponding author    
Abstract
Background: Neonatal respiratory distress syndrome, as a consequence of preterm birth, is a
major cause of early mortality and morbidity during infancy and childhood. Survivors of preterm
birth continue to remain at considerable risk of both chronic lung disease and long-term
neurological handicap. Progesterone is involved in the maintenance of uterine quiescence through
modulation of the calcium-calmodulin-myosin-light-chain-kinase system in smooth muscle cells.
The withdrawal of progesterone, either actual or functional is thought to be an antecedent to the
onset of labour. While there have been recent reports of progesterone supplementation for
women at risk of preterm birth which show promise in this intervention, there is currently
insufficient data on clinically important outcomes for both women and infants to enable informed
clinical decision-making.
The aims of this randomised, double blind, placebo controlled trial are to assess whether the use
of vaginal progesterone pessaries in women with a history of previous spontaneous preterm birth
will reduce the risk and severity of respiratory distress syndrome, so improving their infant's health,
without increasing maternal risks.
Methods: Design: Multicentred randomised, double blind, placebo-controlled trial.
Inclusion Criteria: pregnant women with a live fetus, and a history of prior preterm birth at less
than 37 weeks gestation and greater than 20 weeks gestation in the immediately preceding
pregnancy, where onset of labour occurred spontaneously, or in association with cervical
incompetence, or following preterm prelabour ruptured membranes.
Trial Entry & Randomisation: After obtaining written informed consent, eligible women will be
randomised between 18 and 23+6 weeks gestation using a central telephone randomisation service.
The randomisation schedule prepared by non clinical research staff will use balanced variable
blocks, with stratification according to plurality of the pregnancy and centre where planned to give
birth. Eligible women will be randomised to either vaginal progesterone or vaginal placebo.
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Study Medication & Treatment Schedules: Treatment packs will appear identical. Woman,
caregivers and research staff will be blinded to treatment allocation.
Primary Study Outcome: Neonatal Respiratory Distress Syndrome (defined by incidence and
severity).
Sample Size: of 984 women to show a 40% reduction in respiratory distress syndrome from 15%
to 9% (p = 0.05, 80% power).
Discussion: This is a protocol for a randomised trial.
Clinical Trial Registration: Current Controlled Trials ISRCTN20269066
Background
Respiratory distress syndrome: the burden of disease
Neonatal respiratory distress syndrome, secondary to
immature pulmonary development, is a major cause of
infant mortality and morbidity among infants born pre-
term [1]. Infants born preterm often require mechanical
ventilation [2], with up to 20% of survivors remaining
oxygen dependent at 28 days of age, and 25% being diag-
nosed with chronic lung disease [2]. Additionally, infant
who are born preterm have a recognised increased risk of
hospitalisation within their first year of life[3], and con-
siderable longer-term risk of neurological handicap,
including cerebral palsy[4].
Birth before 37 weeks gestation occurred in 7% of preg-
nancies within Australia during 2002[5], with 2.6% of all
births occurring prior to 34 weeks gestation [6]. However,
this relatively small proportion of total births within Aus-
tralia, accounts for almost 70% of the total perinatal mor-
tality[6]. It has been estimated that 50% of preterm births
occur in the setting of spontaneous preterm labour, or fol-
lowing preterm ruptured membranes [7,8].
The financial costs associated with preterm birth and sub-
sequent admission of the infant to the intensive care nurs-
ery are not inconsiderable, with estimates from the United
States from 1990 suggesting a weekly cost of approxi-
mately $US10,000 per preterm baby, or in excess of $5
billion annually[9]. Not surprisingly, the cost of care
increases for infants of lower birthweight, estimated to be
$140,000 where the birthweight is less than 1000
grams[9]. Those infants who suffer severe disability have
long-term care costs estimated to be more than $100,000
and the cost of lifetime custodial care has been estimated
to reach $450,000[9]. These monetary estimates do not
take account of both the emotional and personal costs to
the family and individuals themselves, which are consid-
erable.
The likelihood of recurrence of preterm birth
Population cohort data suggests that women who have
had a previous preterm birth are more likely to give birth
preterm in a subsequent pregnancy [10-12], with up to a
third of women giving birth prior to 37 weeks gesta-
tion[12]. For 8.2% of women with a previous preterm
birth, subsequent infants will be born at a similar gesta-
tional age[12]. Other authors have estimated the rate of
recurrent preterm birth to be 22.5%[13], which represents
a two and a half fold increase in the risk of preterm birth,
when compared with women who have not had a previ-
ous spontaneous preterm birth[14].
Respiratory distress syndrome: How can we reduce the 
burden of disease?
Reducing an infant's risk of respiratory distress syndrome
requires prevention of preterm birth or interventions to
improve fetal and neonatal lung maturation. To date,
interventions to prevent preterm birth remain elusive. It
has been estimated that in developed nations, the rate of
preterm birth has remained relatively constant between 6
and 10% for the past four decades, despite a multitude of
intervention strategies aimed at various 'at-risk' popula-
tions.
Studies involving the use of progesterone as an agent to
prevent preterm birth date to the 1960's [15], although
with the recent publication of randomised trials, there has
been renewed interest in its use in pregnancy.
The role of progesterone in the initiation of labour
The onset of labour in women is a complex interaction of
different hormonal pathways [16-19], with progesterone
being considered essential to the maintenance of a nor-
mal healthy pregnancy [20-22]. Progesterone has an
important role in maintaining uterine quiescence[23,24],
acting to reduce calcium flux of smooth muscle through
suppression of the calcium-calmodulin-myosin light
chain kinase system[19,21].
There is debate about the previously described progester-
one withdrawal[25] as an antecendent to the onset of
labour[26]. Seven progesterone receptor subtypes have
been classified in women, with alterations in the ratio of
receptor expression resulting effectively in withdrawal ofBMC Pregnancy and Childbirth 2009, 9:6 http://www.biomedcentral.com/1471-2393/9/6
Page 3 of 7
(page number not for citation purposes)
progesterone[26,27], and a resultant increase in the sensi-
tivity of the myometrium to contractile stim-
uli[20,22,28,29].
Documented in many animals is a reduction in serum
progesterone concentrations prior to the onset of labour
[16,19,20,30]. However, this has not been shown to occur
before term or preterm labour in women, with no detect-
able changes in the concentrations of steroid hor-
mones[19,20,22,31,32]. However, the pharmacological
withdrawal of progesterone with inhibitors such as mife-
pristone (RU486), has been used clinically to interrupt
pregnancy and facilitate termination [33,34], while pro-
gesterone has been used to maintain pregnancy in women
undergoing assisted reproductive techniques, until pla-
cental production suffices[35].
Progesterone is also known to have anti-inflammatory
properties, raising a potential link between inflammatory
processes, alterations in progesterone receptor expression
and onset of preterm labour [36].
Safety of progesterone
The use of natural progesterone in pregnancy has been
considerable, without documented effect on the risk of
congenital anomalies or other aspects of fetal develop-
ment[37,38]. Animal studies in sheep have suggested that
prolonged exposure to high concentrations of progester-
one may affect fetal behavioural states[39], with suppres-
sion of activity and arousal[40,41]. Further information
about the effect of prolonged exposure of the fetus to pro-
gesterone therapy during pregnancy is required.
Maternal side effects related to progesterone therapy are
minor and of a temporary nature, including headache,
nausea, breast tenderness, and coughing.
The clinical evidence for the use of progesterone in the 
prevention of preterm birth: The Cochrane Review
The use of progesterone in pregnancy for the prevention
of preterm birth has been evaluated in a Cochrane system-
atic review[42], in which seven randomised trials were
identified comparing intramuscular 17 alphahydroxypro-
gesterone caproate with placebo[15,43-48]. Two trials
were excluded as they adopted a quasi-randomised
method of treatment allocation[15,47]. In a meta-analysis
of these five trials, women who received progesterone had
a statistically significant lower risk of preterm birth and in
keeping with this, fewer infants with birth weight less than
2.5 kg when compared with those women administered
placebo[42]. There was insufficient evidence to assess the
effects of progesterone therapy on perinatal death or res-
piratory distress syndrome, with a single trial only[45]
reporting information regarding neonatal morbidity.
However, intra-muscular 17 alpha-hydroxyprogesterone
caproate is not available for general prescription in Aus-
tralia, North America, or the United Kingdom.
A single randomised trial was identified comparing vagi-
nal progesterone pessaries with placebo[49], in which 157
Brazilian women with a singleton pregnancy considered
to be at "high risk" of preterm birth (history of previous
preterm birth, the presence of a cervical suture, or uterine
malformation), were recruited. Women were randomised
to receive either 100 mg progesterone or placebo suppos-
itories administered nightly between 24 and 34 weeks ges-
tation[49]. While there were fewer women in the
progesterone group who gave birth before 37 weeks gesta-
tion (10/72 (13.9%) progesterone versus 20/70 (28.6%)
placebo; relative risk 0.49; 95% Confidence Intervals
0.25–0.96; p = 0.03), there were no other maternal or
infant health outcomes reported[49].
To summarise
There are limitations of the current evidence on the use of
vaginal progesterone for women at increased risk of pre-
term birth, including the lack of reporting of maternal and
infant outcomes; the lack of information about potential
harmful fetal and infant effects related to in-utero expo-
sure to progesterone related to the use of vaginal proges-
terone.
Aims of the trial
The aims of this randomised, double blind, placebo con-
trolled trial are to assess whether the use of vaginal proges-
terone pessaries in women with a history of previous
spontaneous preterm birth will reduce the risk and sever-
ity of respiratory distress syndrome, so improving their
infant's health, without increasing maternal risks.
Trial hypotheses
The primary hypothesis of this randomised trial is that
the administration of progesterone to women with a his-
tory of previous spontaneous preterm birth will
• reduce the risk of neonatal respiratory distress syn-
drome.
The secondary hypotheses of this randomised trial are
that the administration of progesterone to women with a
history of previous spontaneous preterm birth will
￿ reduce the risk of morbidity from neonatal lung dis-
ease;
￿ reduce the risk of morbidity from other adverse out-
comes for the infant; and
￿ reduce the risk of maternal morbidity without adverse
effects of therapy.BMC Pregnancy and Childbirth 2009, 9:6 http://www.biomedcentral.com/1471-2393/9/6
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Methods/Design
Study Design
Multicentred randomised, double blind, placebo-control-
led trial.
Inclusion Criteria
Pregnant women with a live fetus confirmed at the time of
trial entry between 18 and 236 weeks gestation, who have
a history of prior preterm birth at less than 37 weeks ges-
tation and greater than 20 weeks gestation (either vaginal
birth or caesarean birth) in the immediately preceding
pregnancy, where the onset of labour occurred spontane-
ously, or in association with cervical incompetence, or fol-
lowing preterm prelabour ruptured membranes. Women
who receive progesterone therapy early for early preg-
nancy support (prior to 16 weeks gestation) in the current
pregnancy will be eligible for trial inclusion.
Exclusion Criteria
Women with the following will not be eligible for partici-
pation:
￿ Women whose immediately preceding preterm birth at
less than 37 weeks gestation was associated with:
m Placental abruption or placenta praevia
m Multiple pregnancy
m Iatrogenic decision for early birth (for example related
to fetal distress, preeclampsia, eclampsia)
￿ Women whose current pregnancy is associated with:
m Active vaginal bleeding requiring hospital admission
after 17+6 weeks of gestation
m Current preterm prelabour ruptured membranes diag-
nosed prior to trial entry
m Active labour (defined as the presence of uterine activity
and cervical dilatation greater than 3 cm)
m Known lethal fetal anomaly
m Fetal demise
m Progesterone treatment during the current pregnancy
after 16 weeks gestation
m Any contraindication to continuation of the pregnancy
(eg. chorioamnionitis requiring delivery)
m Any contraindication to progesterone therapy (known
active liver disease, thrombophlebitis, active thromboem-
bolism (or hormone related), breast or genital malig-
nancy).
The use of progesterone in the following conditions is not
contraindicated but the manufacturers recommend use
with monitoring: serious depression and medical condi-
tions that may be aggravated by fluid retention (asthma,
epilepsy, migraine, known cardiac dysfunction, known
renal dysfunction).
Trial Entry
Eligible women will be identified in the antenatal clinic,
given the trial information sheet and counselled by the
researcher, before obtaining informed written consent.
Randomisation will occur between 18 and 23+6 weeks ges-
tation by telephoning the cental randomisation service.
The randomisation schedule will use balanced variable
blocks, and will be prepared by an investigator not
involved with recruitment or clinical care. There will be
stratification of women according to plurality of the preg-
nancy (singleton versus twin pregnancy versus triplet
pregnancy) and centre. Eligible women will be ran-
domised to either vaginal progesterone therapy or vaginal
placebo.
Approval to conduct this study has been obtained from the 
following research and ethics committees
Women's and Children's Hospital (Adelaide, South Aus-
tralia); Modbury Public Hospital (Adelaide, South Aus-
tralia); Flinders Medical Centre (Adelaide, South
Australia); Lyell McEwin Health Service (Adelaide, South
Australia); The Queen Elizabeth Hospital (Adelaide,
South Australia); Mercy Health and Aged Care (Mel-
bourne, Victoria); Royal Women's Hospital (Melbourne,
Victoria); Monash Medical Centre (Melbourne, Victoria);
Sydney West Area Health Service (New South Wales); Syd-
ney South Area Health Service (New South Wales); North-
ern Sydney Central Coast (New South Wales); Sydney
Adventist Hospital (New South Wales); ACT Health (Aus-
tralian Capital Territory); Mater Health Services (Brisbane,
Queensland); Toowoomba Health Service (Queensland);
Ipswich Hospital (Queensland); Redcliffe-Caboolture
Health Service (Queensland); Townsville Health Service
(Queensland); Launceston General Hospital (Tasmania);
Christchurch Women's Hospital (New Zealand); Auck-
land Hospital (New Zealand); Mt Sinai Hospital
(Toronto, Canada).
Study Medication & Treatment Schedules
After randomisation, the woman will be allocated a study
number that corresponds with the same number on her
treatment pack. The woman, her caregivers and research
staff assessing the trial outcomes will be blinded to treat-
ment allocation. Treatment packs will appear identical for
the treatment groups. Women will be asked to self-admin-BMC Pregnancy and Childbirth 2009, 9:6 http://www.biomedcentral.com/1471-2393/9/6
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ister equivalent of 100 mg vaginal progesterone each
evening from 20 weeks gestation, or randomisation (if
this occurs after 20 weeks gestation) until birth or 34
weeks gestation (whichever occurs first). Women who
develop prelabour ruptured membranes after trial entry
will remain in their treatment groups for the purposes of
analysis, but will be advised to discontinue using vaginal
pessaries to reduce the risk of introducing vaginal or
ascending infection.
Follow-up of women in both treatment groups
Women will be reviewed in the antenatal clinic according
to the recommendation of the practitioner responsible for
their care. Women will receive further trial medication
treatment packs on a monthly basis. At 34 weeks gesta-
tion, women will be asked about the occurrence of any
side effects experienced and compliance with the treat-
ment protocol. After birth, information will be obtained
relating to birth and infant outcomes from the woman's
and infant's case notes by the research assistant and the
delivery form completed. Similarly, the postnatal and
neonatal forms will be completed for each live born infant
after discharge from hospital.
Primary Study Endpoints
The primary study outcome is:
￿ Neonatal Respiratory Distress Syndrome (defined by
the incidence (increasing respiratory distress or oxygen
requirement or the need for respiratory support from the
first six hours of life, in a term or preterm infant) and
severity of neonatal respiratory disease (mild = mean air-
way pressure (MAP) < 7 cm H2O, and/or fractional
inspired oxygen (FiO2) < 0.4; moderate = MAP 7–9.9 cm
H2O, and/or FiO2 0.40–0.79; severe = MAP ≥ 10 cm H2O,
and/or FiO2 ≥ 0.80 with need for ventilation)[2].
Secondary Study Endpoints
The secondary study endpoints are:
1) Other respiratory outcomes defined as: main respira-
tory diagnosis (that is, the main indication for respiratory
support for the baby), need for and duration of oxygen
therapy (including highest FiO2  (%) within 12 hours
birth), and need for and duration of mechanical ventila-
tion (including maximum peak pressure (cm H2O) within
12 hours birth), air leak syndrome, need for surfactant
therapy, nitric oxide for respiratory support, and chronic
lung disease (defined as the need for any respiratory sup-
port, supplemental oxygen or intermittent positive pres-
sure ventilation or continuous positive airways pressure
for a chronic pulmonary disorder on the day the baby
reached 36 weeks' postmenstrual age, for infants born
before 32 weeks gestation, or continued oxygen require-
ment at 28 days of age for infants born after 36 weeks ges-
tation).
2) Adverse outcomes for the infant defined as one or
more of the following: preterm birth (defined as birth at
less than 37 weeks gestation) and mortality (defined as
either a stillbirth (intrauterine fetal death after trial entry
and prior to birth), or infant death (death of a live born
infant prior to hospital discharge, and excluding lethal
congenital anomalies)); Apgar score < 4 at 5 minutes of
age; birth weight less than the 3rd centile for gestational
age at birth and infant sex; intraventricular haemorrhage
on early cranial ultrasound; periventricular leucomalacia
on later cranial ultrasound; inotropic support for the treat-
ment of patent ductus arteriosus; proven necrotising ente-
rocolitis; proven systemic infection within 48 hours of
birth and treated with antibiotics; retinopathy of prema-
turity.
3) Adverse outcomes for the woman including length of
antenatal hospital stay; use of tocolytic therapy; antenatal
corticosteroid therapy; side effects of progesterone supple-
mentation (including headache, nausea, breast tender-
ness, coughing); antepartum haemorrhage; pre-
eclampsia; preterm prelabour ruptured membranes;
prelabour ruptured membranes at or near term (defined
as prelabour ruptured membranes after 36 weeks gesta-
tion); chorioamnionitis requiring antibiotic use during
labour; postpartum haemorrhage; antibiotic use after
birth; length of postnatal hospital stay; maternal death;
not breast feeding at four months postpartum.
Sample Size
The clinical endpoint of respiratory distress syndrome has
been chosen as the primary endpoint. For women eligible
for this trial, the best estimate of the incidence of respira-
tory distress syndrome is 15%, using information from a
randomised trial with similar eligibility profile[45]. A
sample size of 984 women will be able to show a 40%
reduction in respiratory distress syndrome from 15% to
9% (5% level of significance, two-tailed alpha, 80%
power).
Analysis and Reporting of Results
The initial analysis will examine baseline characteristics of
all randomised women, as an indication of comparable
treatment groups. Outcome comparisons for women and
infants will be analysed for the primary and secondary
outcomes on an "intention to treat" basis, according to
treatment allocation at randomisation to either progester-
one or placebo. The relative risks and 95% confidence
intervals will be reported for the major outcomes, and the
number needed to treat to prevent one adverse outcome
will be calculated. Regression techniques will be used toBMC Pregnancy and Childbirth 2009, 9:6 http://www.biomedcentral.com/1471-2393/9/6
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examine the influence of prognostic factors on the major
outcomes.
Discussion
This is a protocol for a randomised trial assessing the role
of vaginal progesterone in women with a previous spon-
taneous preterm birth. The findings of this trial will con-
tribute to the currently available literature regarding the
use of vaginal progesterone.
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